Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.35 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28378455 | 1.00 | POLRMT (0.47) | POLRMTDOT1LTMPRSS2STING1MAP4K4 | |
| SCHEMBL19768739 | 0.90 | POLRMT (0.46) | POLRMTDOT1LTMPRSS2STING1MAP4K4 | |
| SCHEMBL16708508 | 0.90 | POLRMT (0.46) | POLRMTDOT1LTMPRSS2STING1MAP4K4 | |
| SCHEMBL19779087 | 0.90 | POLRMT (0.46) | POLRMTDOT1LTMPRSS2STING1MAP4K4 | |
| Hydrochloric Acid SCHEMBL25392678 | 0.89 | POLRMT (0.45) | POLRMTDOT1LTMPRSS2STING1MAP4K4 | |
| Hydrochloric Acid SCHEMBL25392672 | 0.88 | POLRMT (0.45) | POLRMTDOT1LTMPRSS2STING1MAP4K4 | |
| SCHEMBL26828475 | 0.86 | POLRMT (0.47) | POLRMTDOT1LTMPRSS2STING1MAP4K4 | |
| SCHEMBL25434682 | 0.85 | POLRMT (0.47) | POLRMTDOT1LTMPRSS2STING1PIK3CD | |
| SCHEMBL25386328 | 0.85 | POLRMT (0.47) | POLRMTDOT1LTMPRSS2STING1PIK3CD | |
| SCHEMBL31216435 | 0.84 | POLRMT (0.42) | POLRMTDOT1LTMPRSS2STING1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885DOT1L 3143/4885TMPRSS2 324/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885DOT1L 3143/4885TMPRSS2 324/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885DOT1L 3143/4885TMPRSS2 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.